HD-PLC began to demonstrate the use of IoT in factories and large-scale facilities 20170905

By Communication, JPN

 

Panasonic Corporation will begin demonstration experiments to expand the range of use of high-speed PLC technology “HD-PLC” (Note 1) developed by the company. This demonstration experiment is intended for use as a communication purpose for factory and large scale facility, such as three-phase power line for motive power system and three-phase power line of backbone used for LED lighting. By using existing power lines, wiring of new communication wires becomes unnecessary, and it can be utilized also in the place of radio insensitivity. In addition, it is possible to realize a system with 1000 connected terminals with IEEE 1901 which is an international standard of high-speed PLC, by making multi-hop technology ITU-T G.9905 correspond (hereinafter “HD-PLC” multihop) I will. This makes it possible to hop between multiple terminals, enable long distance communication of about several Km (Note 2) using power lines, network press release at large-scale facilities, etc. | Panasonic Newsroom Japan

 

http://news.panasonic.com/jp/press/data/2017/09/jn170905-1/jn170905-1.html

More from tokioX :

  1. LED comm: Toppan Printing, large capacity wireless comm with LED – without communication cable
  2. 📡NICT: A network that can be connected even at speeds of 500 km / h is realized
  3. ⛴Mitsui engineering & shipbuilding, high pressure EGR system compatible with NOx tertiary regulation adopted for large marine diesel engine coal carrier
  4. 📡Research Institute: Actual operation of new optical network by silicon photonics began – Expectation for practical application of ultra high definition ultra low delay video service –
  5. 📡Panasonic Will Bring to Market Aspherical Glass Lenses (Square Type) for Compact High-speed Optical Transmission Modules
  6. Development of the world’s first high-speed integrated photodetector that simultaneously converts many optical signals to electric signals   2017/09/14
  7. Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients   20170911